Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer

BackgroundBone flare has been observed on 99mTc-MDP bone scans of patients with metastatic castration-resistant prostate cancer (mCRPC). This exploratory study investigates bone flare in mCRPC patients receiving androgen receptor (AR) inhibitors using 18F-NaF PET/CT.MethodsTwenty-nine mCRPC patients...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2019-05, Vol.22 (2), p.324-330
Main Authors: Weisman, Amy J., Harmon, Stephanie A., Perk, Timothy G., Eickhoff, Jens, Choyke, Peter L., Kurdziel, Karen A., Dahut, William L., Humm, John L., Apolo, Andrea B., Larson, Steven M., Morris, Michael J., Perlman, Scott B., Liu, Glenn, Jeraj, Robert
Format: Article
Language:English
Subjects:
Androgen receptors
Bone cancer
Castration
Computed tomography
Fluorine isotopes
Inhibitors
Lesions
Metastases
Metastasis
Patients
Positron emission
Prostate cancer
Schedules
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundBone flare has been observed on 99mTc-MDP bone scans of patients with metastatic castration-resistant prostate cancer (mCRPC). This exploratory study investigates bone flare in mCRPC patients receiving androgen receptor (AR) inhibitors using 18F-NaF PET/CT.MethodsTwenty-nine mCRPC patients undergoing AR-inhibiting therapy (abiraterone, orteronel, enzalutamide) received NaF PET/CT scans at baseline, week 6, and week 12 of treatment. SUV metrics were extracted globally for each patient (SUV) and for each individual lesion (iSUV). Bone flare was defined as increasing SUV metrics or lesion number at week 6 followed by subsequent week 12 decrease. Differences in metrics across timepoints were compared using Wilcoxon tests. Cox proportional hazard regression was conducted between global metrics and progression-free survival (PFS).ResultsTotal SUV was most sensitive for flare detection and was identified in 14/23 (61%) patients receiving CYP17A1-inhibitors (abiraterone, orteronel), and not identified in any of six patients receiving enzalutamide. The appearance of new lesions did not account for initial increases in SUV metrics. iSUV metrics followed patient-level trends: bone flare positive patients showed a median of 72% (range: 0–100%) of lesions with total iSUV flare. Increasing mean SUV at week 6 correlated with extended PFS (HR = 0.58, p = 0.02).ConclusionNaF PET bone flare was present on 61% of mCRPC patients in the first 6 weeks of treatment with CYP17A1-inhibitors. Characterization provided in this study suggests favorable PFS in patients showing bone flare. This characterization of NaF flare is important for guiding treatment assessment schedules to better distinguish between patients showing bone flare and those truly progressing, and should be performed for all emerging mCRPC treatments and imaging agents.
ISSN:1365-7852
1476-5608
DOI:10.1038/s41391-018-0110-5